Holista Colltech Limited · ASX:HCT
Holista Colltech — Shareholder Meeting (May 2026)
11 slides from Holista Colltech's shareholder meeting presentation, May 25, 2026
Slide 1: Annual General Meeting 2026: Rebuilding Through Governance, Discipline and Strategic Execution
Holista Colltech Limited Annual General Meeting 2026 For personal use only REBUILDING THROUGH GOVERNANCE, DISCIPLINE AND STRATEGIC EXECUTION Presented by : Mr.Leong Man Loong, CEO and Executive Director of Holista Colltech 25 May 2026
Slide 2: Holista's Transformation
Holista's Transformation • Refreshed Board and stronger For personal use only governance • Major legacy legal matters substantially resolved • Liquidity position stabilised • Leaner operating structure • Focus returned to execution and commercialisation
Slide 3: FY2025 Financial Overview
FY2025 Financial Overview FY 2025 Financial Results AUD’000 Loss before tax (909) For personal use only Debt recoveries (842) ASIC settlement 1,090 ProImmune legal fee 394 FY 2025 Loss excluding One -Off items (267) Cost Reduction initiatives AUD’000 Staff cost reduction 380 Directors’ fee reduction
Slide 4: Final Major Transition
Final Major Transition Headwinds Improvements ASIC penalty and legal Cost base materially For personal use only costs reduced ProImmune litigation Cash management and settlement tightened Legacy restructuring Governance framework activities strengthened Ongoing market Operations stabilised confidenc
Slide 5: Charting Recovery
Charting Recovery For personal use only Major legacy legal issues have largely been addressed. Efforts made to improve governance and business certainty. Clear strategic direction moving forward .
Slide 6: Collagen Remains Central to Holista's Strategy
Collagen Remains Central to Holista’s Strategy For personal use only • Higher -value nano -collagen applications • Nutraceutical opportunities • Cosmetic applications • Biomedical and wound -care potential • IP-led commercial model
Slide 7: SCC Joint Venture
SCC Joint Venture • RM5 million funding support; Lower - capex restart structure; For personal use only • Shared operational risk; Faster pathway toward recommissioning • Access to broader market development support through SCC’s channels • Holista retains ownership of existing and future IP • Reven
Slide 8: Collie Facility 2.0
Collie Facility 2.0 For personal use only • New modular production facility; replaces old facility (expired lease) • Nano-collagen capability integrated into plant design • Lower fixed operating structure • Existing collagen buffer stock available • Land approvals in progress; set up of approx. 6 mo
Slide 9: Regenerex Collaboration
Regenerex Collaboration For personal use only • Strategic collaboration with Regenerex Pharma • Progression of regulatory and trial activities • Potential medical and wound -care applications • Commercialisation pathway remains milestone-driven • Placed order USD52k
Slide 10: Focus Areas: FY2026 & Beyond
Focus Areas : FY2026 & Beyond For personal use only • Progress collagen recommissioning • Execute SCC JV roadmap • Advance strategic partnerships • Strengthen recurring revenue streams • Settle remaining legal issues – ProImmune and legal costs of ASIC matter • Continue governance and operational di
Slide 11: Thank You
For personal use only Thank You